- Presentation to Include Additional Positive Data from the Recently Completed PRIME Clinical Study - SAN DIEGO, CA / ACCESS Newswire / January 14, 2026 / Revelation Biosciences Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, announced today that new clinical data on the potential therapeutic benefit of Gemini for the treatment of acute kidney injury (AKI) and chronic kidney disease (CKD) will be presented at the Interna ...

SAN DIEGO, CA / ACCESS Newswire / January 7, 2026 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the "Company" or "Revelation"), a clinical-stage life sciences company that is focused on rebalancing inflammation, today announced the start of GMP manufacturing of GEMINI and placebo. This manufacturing run will provide the Company with clinical drug supply for later stage clinical studies. "We are delighted to be working with a leading global contract manufacturing organization," said James Rolke, Chief Execut ...

Core Insights - Revelation Biosciences, Inc. has successfully submitted and received acceptance for the end-of-phase 1 meeting package to the FDA [1] - The company is on track to hold the meeting later this year, which aims to gather agency feedback on the clinical development and regulatory approval pathway for Gemini as a treatment for acute kidney injury (AKI) [1] Company Developments - The primary focus of the meeting with the FDA is to establish feedback regarding the clinical development of Gemini [1] - The company is positioned as a clinical-stage life sciences entity concentrating on rebalancing inflammation [1]

Core Insights - Revelation Biosciences, Inc. is focused on rebalancing inflammation and has made significant progress in its Phase 1b PRIME clinical study for stage 3 and 4 chronic kidney disease (CKD) patients [1] - The primary endpoint of the study, which evaluates the safety and tolerability of escalating doses of Gemini, has been successfully met [1] - The company is set to host a corporate update webcast/conference call to discuss the groundbreaking activity data from the clinical study [1] Company Overview - Revelation Biosciences, Inc. is a clinical-stage life sciences company [1] - The company aims to potentially revolutionize the treatment of acute and chronic inflammatory diseases through its innovative approach [1] Clinical Study Details - The Phase 1b PRIME clinical study focuses on patients with stage 3 and 4 CKD [1] - The study's results indicate a normalization of the inflammatory response at the cellular level in these patients [1]